Gsa Capital Partners LLP Design Therapeutics, Inc. Transaction History
Gsa Capital Partners LLP
- $1.32 Billion
- Q3 2024
A detailed history of Gsa Capital Partners LLP transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 173,744 shares of DSGN stock, worth $1.05 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
173,744
Previous 209,953
17.25%
Holding current value
$1.05 Million
Previous $703,000
33.0%
% of portfolio
0.07%
Previous 0.05%
Shares
8 transactions
Others Institutions Holding DSGN
# of Institutions
102Shares Held
30.3MCall Options Held
2.3KPut Options Held
16.5K-
Sr One Capital Management, LP6.53MShares$39.3 Million11.88% of portfolio
-
Logos Global Management LP San Francisco, CA4.22MShares$25.4 Million3.0% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$13.9 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.89MShares$11.4 Million0.55% of portfolio
-
Baker Bros. Advisors LP New York, NY1.74MShares$10.5 Million0.1% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $336M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...